Skip to content
A Green Sign – Lifestyle
Author:
Chiesi Global Rare Diseases
Chiesi Global Rare Diseases Highlights Advancements in Lipodystrophy Research at ENDO 2026
June 18, 2026
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)
March 9, 2026